You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 11,254,652

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,254,652 protect, and when does it expire?

Patent 11,254,652 protects PYRUKYND and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.

Summary for Patent: 11,254,652

Patent landscape, scope, and claims:

Title:	Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfon- amide
Abstract:	Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency. ##STR00001##
Inventor(s):	Sizemore; Jacob P. (Cambridge, MA), Guo; Liting (Suzhou, CN), Mirmehrabi; Mahmoud (Halifax, CA), Su; Yeqing (Halifax, CA)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	16/765,456
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,254,652

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,254,652

PCT Information
PCT Filed	November 21, 2018	PCT Application Number:	PCT/US2018/062197
PCT Publication Date:	May 31, 2019	PCT Publication Number:	WO2019/104134

International Family Members for US Patent 11,254,652

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018373122	⤷ Subscribe
Australia	2024200724	⤷ Subscribe
Brazil	112020010185	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.